Comment: Reasonable to conclude that pembrolizumab is non-inferior to chemotherapy

Bookmark and Share
Published: 1 Jun 2019
Views: 247
Rating:
Save
Dr Richard Schilsky and Dr Josep Tabernero

Dr Richard Schilsky and Dr Josep Tabernero comment on data, during a press conference at the 2019 American Society of Clinical Oncology (ASCO) Annual Meeting, from the KEYNOTE-062 trial.

This was a phase III randomised trial studying the use of pembrolizumab in patients with advanced gastric or gastroesophageal junction as a comparable alternative to chemotherapy.

Watch the original press conference here, and following interview with Dr. Tabernero here.